CTN 300: The Engage Cohort Study

Background

Modern HIV prevention strategies come in many different forms. Biomedical technologies such as pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP) for HIV-negative individuals, and Treatment as Prevention (TasP; screening, antiretroviral (ARV) treatment and care retention) for HIV-positive individuals, are successful in decreasing HIV transmission.; an important key population to focus on that benefit from these HIV prevention strategies. Other prevention approaches, such as educational and safer sex counselling programs, especially in conjunction with other strategies, are also effective. However, uptake and exposure to these programs may differ between cities and between different groups of people. While gbMSM represent a small minority of the Canadian population, they account for half of prevalent HIV cases and half of new HIV diagnoses in Canada. Therefore, an understanding of the evolving impact of ARV-based HIV prevention within this key population, in the context of other effective prevention approaches, is essential at this critical time.

Vel et tristique magna quam. Amet vel ac non nunc. Ut enim, amet, vestibulum lorem id enim elit, feugiat facilisis. Posuere erat eu ut consequat nunc. Amet egestas donec eros amet ultricies mi aliquam. Non eget semper mollis enim scelerisque malesuada eget. Porttitor pretium nibh nibh vitae convallis. Diam at et consequat viverra felis, purus. Et odio mollis facilisis proin cras ullamcorper integer tortor. Sit tincidunt viverra turpis aliquet enim. Quam neque nibh rhoncus tortor. Neque sed dolor aliquet sagittis, malesuada.